What Is AHK-Cu?

Published August 2026 · Patriot Labs Research Team · ~14 min read

AHK-Cu is a copper-binding tripeptide. The name is the recipe: Alanine, Histidine, Lysine — three amino acids in sequence — plus Cu, the chemical symbol for copper. Put together, it is a very small peptide carrying a single copper(II) ion in a defined chemical grip. In cosmetic ingredient nomenclature it is listed as copper tripeptide-3, which is worth knowing because that is the name it appears under in formulation literature. Its far more famous sibling, GHK-Cu, is copper tripeptide-1.

The difference between the two molecules is a single methyl group. Swap the glycine at position one for alanine and GHK becomes AHK. That is the entire structural distinction, and it is a useful reminder that in peptide chemistry very small changes are not necessarily small changes — but they are not automatically large ones either. Whether that methyl group matters biologically is exactly the kind of question the literature on AHK-Cu is still too thin to answer confidently.

If you have read our GHK-Cu explainer, treat this guide as the companion piece: same chemical family, same copper-delivery logic, dramatically different depth of evidence.

The chemistry: how a tripeptide holds copper

To understand any copper peptide you have to start with a problem: copper is useful and copper is dangerous, and those two facts have the same cause. Copper cycles readily between its Cu(I) and Cu(II) oxidation states. That redox flexibility is precisely why biology recruits it as an enzyme cofactor — and precisely why loose copper ions in solution are a liability, since the same electron shuffling can generate reactive oxygen species and damage the molecules around it.

Biology's answer is that copper is essentially never free. It is handed between proteins and small molecules that hold it in tightly defined coordination environments. A copper tripeptide is a synthetic version of that same idea: a small, well-characterised chemical cage.

The cage is built from three anchor points along the peptide backbone. In GHK-Cu, which has been characterised in detail, the copper is coordinated by the imidazole nitrogen of the histidine side chain, the alpha-amino nitrogen at the N-terminus, and the deprotonated amide nitrogen of the peptide bond between the first two residues. A carboxyl oxygen from a neighbouring complex can complete a square-planar-pyramidal geometry. The resulting complex is remarkably stable — a reported stability constant of log₁₀ = 16.44, against 8.68 for a simple glycine-histidine copper complex. Roughly eight orders of magnitude of difference, from adding one more residue and one more anchor point.

AHK-Cu shares the architecture that makes this work: an N-terminal amine, a histidine in the second position supplying the imidazole, and the amide nitrogen in between. That arrangement — a free N-terminus with histidine at position two or three — is a recognised high-affinity copper motif in peptide chemistry. The substitution of alanine for glycine changes the residue bearing the N-terminal amine but does not remove any of the three donor atoms.

One honest caveat: the stability constant quoted above is measured for GHK-Cu specifically. We have not seen an equivalently rigorous published figure for AHK-Cu, and it would be sloppy to assume the numbers transfer. Alanine's methyl group is small, but it is not nothing — it adds steric bulk and hydrophobicity right at the coordination site. The reasonable statement is that AHK-Cu binds copper through the same structural motif; the precise affinity is not something we can cite a number for.

Why chelated copper, not copper salt

A fair question: if the interest is in copper, why not simply study copper sulfate? The coordination chemistry above is the answer, and it splits into three practical points.

Redox quenching. When copper is locked into the tripeptide's donor set, its redox behaviour is substantially damped compared with the hydrated free ion. The literature on GHK-Cu describes copper's redox activity as effectively silenced in the complex. This is the difference between delivering copper and delivering a pro-oxidant.

Defined stoichiometry. A 1:1 peptide-to-copper complex is a single characterised chemical entity. A copper salt in a protein-containing medium is a distribution of species, binding opportunistically to whatever is available. For an in-vitro experiment, the first is a variable you control and the second is one you mostly hope about.

Different disposition. A small neutral-ish organic complex does not behave like a solvated metal ion — it partitions differently and interacts with membranes and transporters differently. Whether that produces meaningfully different delivery for AHK-Cu specifically is, again, understudied. But it is the mechanistic premise the whole copper-peptide field rests on.

Why does the copper matter to biology at all? Because it is a mandatory cofactor for a set of enzymes with no substitute. Lysyl oxidase — the enzyme that cross-links collagen and elastin, and therefore governs the tensile integrity of connective tissue — is copper-dependent. So are cytochrome c oxidase in the respiratory chain, Cu/Zn superoxide dismutase in antioxidant defence, tyrosinase in melanin synthesis, and ceruloplasmin in iron handling. Copper availability is not a peripheral detail in connective tissue biology; it is load-bearing.

The primary evidence

Nearly everything written about AHK-Cu traces back to one paper: Pyo, Yoo and colleagues, published in Archives of Pharmacal Research in 2007, titled "The effect of tripeptide-copper complex on human hair growth in vitro." It is worth walking through what that study actually did, because the gap between the paper and how it is often summarised is instructive.

The researchers used two models in parallel:

AHK-Cu was applied across a concentration range of 10⁻¹² to 10⁻⁹ M — picomolar to nanomolar. That is a strikingly low range, and it is a detail worth holding onto. The reported findings were:

• Follicle elongation. AHK-Cu stimulated elongation of human hair follicles in the ex vivo organ culture.
• Cell proliferation. It stimulated proliferation of cultured dermal papilla cells.
• VEGF. The work is associated with elevated production of vascular endothelial growth factor, a signalling protein central to the formation of new blood vessels.
• Apoptosis signalling. The Bcl-2/Bax ratio was elevated and the cleaved forms of caspase-3 and PARP were reduced — a coherent pattern pointing away from programmed cell death.
• The negative result. By flow cytometry, AHK-Cu at 10⁻⁹ M reduced the number of apoptotic DPCs, but that reduction was not statistically significant.

That last bullet rarely survives into secondary write-ups, and it should. The molecular markers moved in a consistent direction while the direct cell-counting measure did not reach significance. The authors' own conclusion was appropriately conditional: AHK-Cu promotes growth of human hair follicles, and the effect may occur through stimulating proliferation and precluding apoptosis of dermal papilla cells. "May" is doing real work in that sentence.

The biology behind those markers

The markers in that study are not arbitrary. Each maps onto a specific piece of follicle biology, and understanding why makes the findings easier to weigh.

Dermal papilla cells are the follicle's control centre. The dermal papilla is a small cluster of specialised fibroblasts sitting at the base of the hair follicle. It is not a passive anchor — it signals to the surrounding epithelial cells and largely determines whether a follicle is in its growth phase, its regression phase, or resting. When a study targets DPCs, it is targeting the tissue that sets follicle behaviour rather than the visible structure downstream of it.

VEGF connects growth to blood supply. Vascular endothelial growth factor drives angiogenesis — the growth of new capillaries. An actively growing follicle is metabolically demanding and needs perfusion to match, and the vascular network around follicles is known to remodel with the growth cycle. A compound that raises VEGF expression in dermal papilla cells is, at least in principle, acting on that coupling. This is also where copper's broader biology and the peptide's specific activity become hard to disentangle, since copper availability itself influences angiogenic signalling.

Bcl-2, Bax, caspase-3 and PARP describe an apoptosis decision. Bcl-2 opposes programmed cell death; Bax promotes it; the ratio between them is a standard readout of which way a cell is leaning. Caspase-3 is an executioner protease, and PARP is one of its substrates — so cleaved caspase-3 and cleaved PARP are downstream evidence that the apoptotic programme actually ran. Fewer cleaved forms plus a higher Bcl-2/Bax ratio is a coherent anti-apoptotic signature. Whether it translates into meaningfully more surviving cells is precisely what the non-significant flow cytometry result leaves open.

The connective-tissue thread. Separately from the follicle work, copper peptides as a class are studied for effects on the extracellular matrix — the collagen-and-protein scaffold cells build tissue on. The mechanistic link is copper-dependent lysyl oxidase, which cross-links collagen and elastin fibres. This is the strand that puts copper peptides in anti-aging research discussions. It is far better established for GHK-Cu than for AHK-Cu.

AHK-Cu vs GHK-Cu

These two get compared constantly, usually with more confidence than the evidence supports. Here is a defensible version:

The temptation is to read the right-hand column as "AHK-Cu is the hair one and GHK-Cu is the skin one." Resist it. That framing describes where the studies happened to be pointed, not a demonstrated difference in tissue selectivity. Nobody has run the head-to-head comparisons across both tissues that would justify the split. What can be said is that the AHK-Cu literature is concentrated on follicle models and the GHK-Cu literature is much broader and much deeper.

What the evidence does not establish

This section matters more than the ones above it. A guide that only relays positive findings is marketing wearing a lab coat.

The evidence base is thin. One frequently cited primary study is a starting point, not a literature. Independent replication in other laboratories, with other follicle donors and other protocols, is what converts an interesting result into a reliable one, and AHK-Cu has not accumulated that.

Isolated tissue is not an organism. An ex vivo follicle has no circulation, no hormonal input, no immune system and no nervous system. It is an excellent model for asking whether a compound acts directly on follicle tissue, and a poor one for predicting what happens in a living body. Cultured dermal papilla cells are a further step removed again — and DPCs are known to change their behaviour and lose characteristics over successive passages in culture.

Picomolar activity cuts both ways. Effects at 10⁻¹² M are impressive on their face. They also mean the result sits in a concentration range where trace contaminants, copper carried in by serum, and small pipetting errors are proportionally large. Low-concentration findings demand tight controls and, above all, replication.

Copper versus peptide is unresolved. If a copper complex produces an effect, how much is the peptide and how much is the copper it delivered? Distinguishing them requires the right controls — the apo-peptide without copper, a copper salt at matched concentration, and an inactive chelator. Any confident claim that AHK-Cu's activity is a property of the AHK sequence rather than of copper delivery is running ahead of the published record.

Topical cosmetic use is a different question entirely. AHK-Cu appears in cosmetic formulations, and formulation performance depends on vehicle, penetration, encapsulation, packaging and pH. None of that is addressed by follicle organ culture, and none of it transfers to a research context.

Handling it at the bench

Copper complexes have handling considerations that ordinary amino-acid peptides do not. General peptide storage practice applies, with additions specific to the metal.

Colour is a crude readout. Copper(II) peptide complexes are coloured — characteristically blue to blue-violet in solution, arising from d-d electronic transitions in the coordinated ion. This makes the material visually distinct from the white lyophilised powders that dominate a peptide inventory. A marked colour shift in a reconstituted solution is worth investigating rather than ignoring; it can indicate a change in the coordination environment.

Reducing agents are the obvious antagonist. The whole point of the chelate is to hold copper in a controlled oxidation state. Strong reducing agents — ascorbic acid being the one most often flagged in formulation literature — act directly against that. This is why cosmetic-chemistry guidance routinely advises against combining copper peptides with vitamin C in the same preparation, and the underlying chemistry is not specific to cosmetics.

pH governs the coordination. The copper-binding motif depends on a deprotonated amide nitrogen. Deprotonation is pH-dependent, so the complex is not equally intact across the whole pH range — sufficiently acidic conditions will protonate the donor set and release copper. Buffer choice is not a neutral decision here.

Chelators in your buffer will compete. EDTA and similar sequestrants bind copper avidly. Introducing them alongside a copper peptide sets up a competition that may quietly strip the metal out of the complex you thought you were studying.

Standard peptide hygiene still applies. Cold, dark, dry, minimal freeze-thaw cycling, and reconstitution practices as covered in our reconstitution guide. Oxidation and hydrolysis do not stop being relevant because a metal is present.

Reading a COA for a metal complex

A certificate of analysis for a copper peptide should answer more questions than one for a plain peptide, and our COA guide covers the general principles. The metal-specific additions:

Purity by HPLC tells you about the organic component. A high chromatographic purity figure speaks to the peptide, and does not by itself confirm that the copper is present at the right stoichiometry or in the right oxidation state.

Mass spectrometry should reflect the complex. A copper-containing species has a distinctive isotope signature — copper has two stable isotopes, ⁵³Cu and ⁶⁵Cu, in roughly a 69:31 natural ratio, producing a characteristic doublet pattern. Its presence is good evidence the metal is genuinely coordinated rather than merely co-present.

Identity confirmation matters more than usual here. AHK and GHK differ by 14 mass units — one methyl group. That is an easy distinction for a mass spectrometer and an impossible one by eye. If you are paying for one and need to know you did not receive the other, the COA is the only place that gets settled.

Check what the batch number refers to. A COA that is not traceable to the specific lot in your hand is a marketing document. This is true of all peptides and is not special to copper complexes, but it is the single most common gap.

Frequently asked questions

What is AHK-Cu? A copper-binding tripeptide — alanine, histidine and lysine complexed with a copper(II) ion. Cosmetic ingredient name: copper tripeptide-3.

How is it different from GHK-Cu? One residue: glycine becomes alanine, adding a single methyl group. Both use a histidine-anchored copper coordination site. The practical difference is that GHK-Cu has decades of literature behind it and AHK-Cu has a small handful of studies.

What did the main study find? That AHK-Cu at picomolar to nanomolar concentrations stimulated elongation of isolated human hair follicles and proliferation of cultured dermal papilla cells, with apoptosis-related markers shifting in an anti-apoptotic direction — though the direct flow-cytometry measure of apoptotic cells did not reach statistical significance.

Is the activity from the peptide or the copper? Not resolved in the published record. Separating them requires apo-peptide and copper-salt controls that the available literature does not settle.

Why is it blue? Coordinated copper(II) absorbs in the visible range via d-d electronic transitions. The colour is a property of the complex, not an additive.

Can it be combined with ascorbic acid? Chemically these work against each other — a strong reducing agent opposes the controlled oxidation state the chelate maintains. Formulation guidance consistently advises keeping them separate.

Is it approved for human use? No. It is sold strictly for in-vitro research and laboratory use only, and is not intended for human consumption.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.